Table 4 Adverse reactions.

From: Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Adverse reaction

ICD (n = 57) N (%)

CD (n = 53) N (%)

Any grade

Grade ≥3

Any grade

Grade ≥3

Anaemia

44 (57.2)

17 (29.8)

46 (86.8)

12 (22.6)

Thrombocytopenia

48 (84.2)

26 (45.6)

35 (66.0)

13 (24.5)

Neutropenia

30 (52.6)

17 (29.8)

28 (52.8)

13 (24.5)

Diarrhoea

31 (54.4)

6 (10.5)

29 (54.7)

1 (1.9)

Constipation

21 (36.8)

0

12 (22.6)

0

Nausea

26 (45.6)

2 (3.5)

22 (41.5)

0

Vomiting

15 (26.3)

2 (3.5)

13 (24.5)

1 (1.9)

Sensory neuropathy

18 (31.6)

3 (5.3)

9 (17.0)

0

Peripheral neuropathy

25 (43.9)

1 (1.8)

17 (32.1)

0

Fatigue

41 (71.9)

4 (7.0)

34 (64.2)

1 (1.9)

Infection

29 (50.9)

12 (21.1)

25 (47.2)

7 (13.2)

Thromboembolic event

0

0

1 (1.9)

0

Oedema/ankle swelling

18 (31.6)

0

10 (18.9)

0

Dyspepsia

7 (12.3)

0

2 (3.8)

0

Rash

12 (21.1)

0

7 (13.2)

0

Dehydration

5 (8.8)

0

3 (5.7)

0

Hypotension

2 (3.5)

0

9 (17.0)

2 (3.8)

Muscle weakness

7 (12.3)

2 (3.5)

8 (15.1)

1 (1.9)

Hyperglycaemia

1 (1.8)

0

8 (15.1)

2 (3.8)

Bleeding

8 (14.0)

3 (5.3)

5 (9.4)

1 (1.9)

Other

48 (84.2)

23 (40.4)

43 (81.1)

17 (32.1)